Major kidney study 'FLOW' stopped 1 year early due to overwhelmingly positive results. The study is evaluating the effect of medication Semagutide commonly known as Ozempic on the progression of diabetic kidney disease.Major kidney study 'FLOW' stopped 1year early due to overwhelmingly positive results. The study isevaluating the affect of medication Semaglutide, commonly known as Ozempic, onthe progression of kidney disease, results of the study are expected to be publishedearly in
Majr kidney study 'FLOW' stopped 1year early due to overwhelmingly positive results. The study isevaluating the affect of medication SeMmaglutide, commonly known as Ozempic, onthe progression of kidney disease, results of the study are expected to be publishedearly in 2024.
https://www.everydayhealth.com/kidney-diseases/ozempic-is-so-beneficial-for-kidney-health-they-just-stopped-a-major-trial-one-year-early/?_cldee=PBfE3K3FNFT_iiB41V8_0mfDQG5lPHkSfH_uvZCvR2xi451-VgCWtUIQhC91hlOn&recipientid=contact-be4d77e92348ec118c62002248159d41-6d8e2db6bb7943ce8097279d979b29bf&esid=fd7b33d7-d26b-ee11-9ae7-000d3a798fb7
Ann: Sonic Healthcare USA signs licence for PromarkerD in the US, page-68
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.04 |
Change
0.015(1.47%) |
Mkt cap ! $133.5M | |||
| Open | High | Low | Value | Volume |
| $1.03 | $1.04 | $1.01 | $45.59K | 44.54K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 812 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 4520 | 1 |
View Market Depth
| Last trade - 15.46pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.03 |
Change
0.015 ( 0.52 %) |
||||
| Open | High | Low | Volume | ||
| $1.04 | $1.04 | $1.02 | 9754 | ||
| Last updated 15.46pm 27/05/2024 ? | |||||
| PIQ (ASX) Chart |